Together, these two cancers account for almost a third of all canine cancers.
Dr. Heather Wilson-Robles, an Associate Professor at Texas A&M University and Chief Medical Officer of Volition Veterinary Diagnostics said: "The proof of concept results in these two very prevalent canine cancers give us confidence to move forward with other Nu.Q Vet assays in our pipeline, and with the larger range of cohorts and trials we have collected and planned.
"Clearly, we still have work to do as this single assay did not detect one of the other top five canine cancers, canine osteosarcoma, which was the third cancer tested in this study. However, I am delighted to see such positive results in these two significant cancers and look forward to reporting further data over the coming quarters with additional Nu.Q Vet assays, this time tested on an automated platform.”
Dr. Terry Kelly, Chief Scientific Officer of Volition America said: “It is exciting to see such strong results from our first Nu.Q Vet study conducted at Texas A&M University Veterinary Hospital. It is also interesting to note the similar patterns of detection seen in both canine and human samples confirming that the Nu.Q platform does appear to be useful in more than just human diagnostics.
"As with human diagnostics, there are currently no accurate, simple, affordable cancer screening tests available in veterinary medicine and yet 25% of dogs will develop cancer at some stage of their life. I look forward to completing the planned trials and to launch our first Nu.Q Vet product in the U.S. that we expect to occur in 2020."
Idexx Laboratories has launched a new renal function test, Idexx SDMA, which the company says can detect chronic kidney disease (CKD) in dogs or cats months or even years earlier than traditional methods.
The test is based on a new renal biomarker - symmetric dimethylarginine (SDMA) - and is the result of collaboration with a number of global experts.
Simon Wootton, UK CAG Marketing Manager at Idexx said: "The high sensitivity of this marker for detecting CKD will allow vets to diagnose the disease a lot sooner than has been previously possible. Identifying the disease earlier will give vets more time to intervene and prescribe an appropriate course of action."
The company says that the Idexx SDMA test can identify renal disease in dogs up to nine months earlier than previous methods, while in cats the detection time can be up to 17 months earlier.
Dr Martha Cannon, BA VetMB DSAM(fel) RCVS Recognised Specialist in Feline Medicine of the Oxford Cat Clinic, said: "The launch of SDMA testing is very exciting. It offers the prospect of identifying chronic kidney disease at an earlier stage, which should mean we can treat it more effectively and allow us to maintain cats in the asymptomatic phase. This can improve longevity, but more importantly could help maintain a better quality of life for longer.
"SDMA is also unaffected by muscle loss, which will allow us to assess the true extent of CKD in our elderly and underweight cats. This will lead to improved treatment choices, better quality of life and more peace of mind for owners."
The value of the new test has been validated by the adoption of SDMA into the International Renal Interest Society (IRIS) guidelines as a biomarker for the early detection of CKD.
Jonathan W. Ayers, President and Chief Executive Officer of Idexx Laboratories, said: "Idexx SDMA is a result of our commitment to lead the industry in sustained research investments that serve to advance veterinary medicine. It represents a significant achievement in veterinary diagnostics. Hospitals in the USA already using Idexx SDMA have told us that it has transformed the way renal disease is diagnosed and treated."
Idexx SDMA is available to UK and Ireland reference laboratory customers now. Further information is available at www.idexxsdma.com.
Video shows Sylvia Conway MRCVS, UK Medical Affairs Consultant at Idexx, talking about the new test (can also be viewed here).
The UK's first online gastric ulcer risk assessment for horse owners has just been launched as part of the 2009 Gastric Ulcer Awareness Month (GUAM), organised by Merial Equine Health.
Merial has developed the risk online questionnaire to enable owners to evaluate their horse's risk of ulcers. By logging on to the website http://www.gastriculcerrisk.co.uk/, owners, trainers and riders can complete a form which then returns the results via email. Where an animal is considered to be at medium to high risk, owners will be advised to consult their veterinary practice.
The company's Dr Emma Batson said: "Since the first GUAM in 2007, significant progress has been made in developing awareness and understanding of equine gastric ulcer syndrome.
"However there is still more to do! Our goal is to move gastric ulcers further up the diagnostic process, such that the condition is an early consideration for all horses presented with the vague symptoms associated with ulceration. We know that due to the vague nature of the symptoms, many of horses are suspected of other ailments such as back and teeth problems, general poor performance, or behavioural issues prior to being diagnosed with ulcers.
"This new initiative has been developed through consultation with practising internal medicine specialists. We hope it will help to highlight more cases and encourage clients into the practice with horses that are at genuine risk of ulcers. Further diagnosis, treatment and management measures can then be considered in consultation with the client.
"The website also has a veterinary page so that follow up information and any gastroscopy results can be recorded by the vet. We hope that this feedback will help generate some valuable data for the industry."
To help you promote this initiative, Merial has produced an impactful poster for use in practice waiting rooms, along with educational literature. The poster will be available as a loose insert in various publications during April and May.
For those practices which require a referral scoping service, Merial can put you in touch with three specialist consultants; Rachael Conwell (North) Dr.Tim Brazil (Midlands/nationwide) and Richard Hepburn (South West) who each provide a mobile scoping clinic.
Merial is also promising support for the mobile scoping service for the five practices that direct the largest number of clients to http://www.gastriculcerrisk.co.uk/
A number of events are also taking place during the month for vets, trainers and horse owners, including the following CPD events:
GUAM is supported by BEVA and Dr Batson hopes that the 2009 initiatives will further boost awareness, understanding and diagnosis of this underrated condition.
Idexx Laboratories has announced the addition of pradofloxacin (Veraflox, Bayer Animal Health) to the list of antibiotics that it tests samples sent for culture and sensitivity testing against.
The company says that in the past, only a small percentage of the 350-400 samples it processes every day included a specific request from veterinary surgeons to include sensitivity testing to pradofloxacin. The now-routine testing for pradofloxacin is a positive move toward better clinical outcomes in difficult cases, including specific indications such as wound infections, superficial and deep pyoderma, and in cases with infections resistant to other antibiotics.
Idexx says that as the only next generation fluoroquinolone, pradofloxacin has been shown to be the least likely veterinary fluoroquinolone to select for resistance1, giving vets a lower risk option, when they decide to use an antibiotic from this class.
Matt Jones, Microbiology Manager at Idexx Laboratories said: 'Removing the need to specifically request samples to be tested for sensitivity to pradofloxacin has streamlined the culture and sensitivity testing process for vets and will make it easier for them to adhere to good practice in antibiotic prescription.
"This is important, as antimicrobial resistance is an area of deep international concern. Idexx are pleased to be helping vets identify those cases for which pradofloxacin may be effective and believe that, where indicated, it will lead to improved compliance and excellent clinical outcomes with the added benefit of reducing the likelihood of selecting for resistance, when compared to older generation fluoroquinolones."
The company says this move is in line with BSAVA's PROTECT initiative, which stresses the importance of culture and sensitivity, especially when prescribing antibiotics of the fluoroquinlone class.
Reference
The existing MSD Animal Health Connect Bursary and Ruminant Research Bursary have been combined into the new MSD Animal Health Research Bursary which is designed to support the future of the veterinary profession through research.
The student arm of the new Research Bursary will award £1,000 to the five best research project applications received from veterinary students across all UK veterinary schools, with an opportunity for an additional £1,000 top prize and £500 runner-up prize.
The veterinary surgeon arm of the Research Bursary will offer three awards, consisting of two ruminant awards and one companion animal award, of up to £4,000 each. The veterinary practitioner proposals will be judged by University academics to ensure independent assessment.
Michelle Townley, Veterinary Advisor at MSD Animal Health said: "Our existing Research Bursaries are well known amongst students and practitioners, having run for over 25 years for the student bursary and 6 years for the ruminant bursary. To increase our support for the veterinary profession through research we have decided to combine our Research Bursaries and add some new categories to help appeal to as wide an audience as possible. This way we can offer a broader level of support for both existing companion animal and ruminant practitioners and our veterinary surgeons of the future. We aim to engage as many people as possible so the MSD Animal Health Research Bursary will be supported by a new website page and social media package to encourage as much interest from students and practitioners as possible."
Student bursary applications are now invited, with a deadline for entries of Friday 26th May 2017. Veterinary practitioners will be invited to apply in September 2017.
For further details go to the MSD Animal Health Research Bursary website at www.msd-animal-health.co.uk/researchbursary.aspx.
Judges for the UK Rabbit Vet of the Year, the Rabbit Nurse of the Year and the Rabbit Veterinary Practice of the Year awards will be looking for exceptional knowledge of rabbit care and husbandry, and evidence of the winners’ continued commitment to educating the public on how to care for rabbits correctly.
Dr Suzanne Moyes MVB MRCVS, awards judge and Veterinary Director at Burgess Pet Care said: "These awards are our way of saying ‘Thank You’ to the veterinary professionals that are helping to improve the lives of pet rabbits."
Rae Todd, Director of the Rabbit Welfare Association & Fund said: "Rabbits make absolutely fantastic pets but research continues to show that there are still too many rabbit owners failing to meet the correct needs of their rabbits. We’re incredibly grateful for the growing number of vets that are working hard to address this, whether that’s by utilising the available rabbit CPD, taking part in events like Rabbit Awareness Week or generally making their practices more suitable environments for rabbit-owning clients."
Veterinary surgeons and nurses can self-nominate for these awards, and nominations are also being sought from the public.
The winners will each receive a cash prize of £500.
To enter the awards, visit www.burgesspetcare.com/excel-vet-awards.
The campaign comprises of a series of live interviews, articles and surveys aimed at exploring the impact of breast cancer, menopause, infertility and baby loss women, and men, and how the veterinary profession can better support people having to cope with these issues in the workplace.
The campaign includes free access articles and live online sessions with VetYourBreasts campaign organiser, veterinary surgeon Anna Beber, as part of Breast Cancer Awareness Month; VetMINDS co-founder, vet Nat Scroggie, on 12th October during Baby Loss Awareness Week; Dr Karen Morton, consultant obstetrician and gynaecologist on World Menopause Day 18th October; and SPVS Senior Vice President, Catriona Curtis, talking about her personal experiences with infertility on 2nd November during National Fertility Week.
A survey on the impact of the menopause, particularly on working life, is being run in partnership with SPVS in the run up to World Menopause Day. The survey seeks to gain a broad understanding of both awareness and experience across the profession, and responses are encouraged from all ages and genders, whether personally affected or not. The survey can be accessed here until 15th October: https://bit.ly/2FVXIkv
SPVS President, Anna Judson, said: "Having experienced the effects of the menopause working as a practice owner, I wish I had known more about the impact and that I was not alone in how I was feeling. There is a growing appetite to tackle these issues and we want to hear from anyone affected by the menopause, in order to put the right support mechanisms in place. We're proud to sponsor the menopause webinar and partner with Veterinary Woman on raising awareness about health issues, which are often brushed under the carpet."
Liz Barton, editor of Veterinary Woman, said: "I have been incredibly moved to see the deep empathy and encouragement amongst veterinary colleagues beginning to open up about the impact of health challenges, particularly at work. When I realised the campaigns in October were topics we need to talk about more as a profession, it seemed right to use this as a platform to tackle some of the hidden, emotive health challenges we bear throughout our life and work. We are looking for partners to help us develop the conversations and practical assistance for individuals and practices, to better support those who are silently living with these burdens."
Companies and organisations wishing to support the work should contact liz@veterinarywoman.co.uk. Individuals can register for updates about how to access the sessions by joining the Veterinary Woman email list for updates (www.veterinarywoman.co.uk), or following Veterinary Woman on social media.
'Period prevalence and mortality rates associated with hypocholesterolaemia in dogs and cats: 1,375 cases1' determined the period prevalence of hypocholesterolaemia and the associated mortality rates in dogs and cats at the Veterinary Medical Teaching Hospital, University of California, Davis.
The medical records of cats and dogs presenting to the hospital from 1st September 2011 to 30th August 2016 were retrospectively reviewed to identify all animals that had at least 1 cholesterol measurement; a total of 16,977 dogs and 3,788 cats were identified. Patient signalment and clinical information were collated from the medical records, including the primary disease processes in patients with moderate to severe hypocholesterolaemia. The period prevalence and mortality rate of hypocholesterolaemia were calculated.
The period prevalence of hypocholesterolaemia was 7.0% in dogs and 4.7% in cats. The mortality rate of hypocholesteraemic dogs and cats was 12% in both species, which was significantly higher than that of animals with normal serum cholesterol.
Steven Epstein, corresponding author for the paper, said: 'The odds of death in dogs and cats with hypocholesterolaemia were 3.2 and 2.5 times higher than in those with normocholesterolaemia respectively. Furthermore, there was a significant linear trend towards higher mortality in association with more severe hypocholesterolaemia in both species.
'Disease of the hepatic, gastrointestinal and lymphoreticular systems were most commonly associated with hypocholesterolaemia, and infectious and neoplastic disease were the most commonly associated pathophysiological processes in both species. In dogs with neoplasia, lymphoma was over-represented.'
Nicola Di Girolamo, Editor of JSAP said: 'These findings suggest that low cholesterol levels are associated with mortality in canine and feline patients. It is not clear whether hypocholesterolaemia is simply a marker for disease severity, or if it has active physiological effects contributing to poor outcomes. At this stage, it seems indicated to enhance intensity of diagnostic effort and therapy for affected animals.'
The full article can be found in the November issue of the Journal of Small Animal Practice which is free for BSAVA members. It can also be read online here: https://www.onlinelibrary.wiley.com/doi/10.1111/jsap.13204
The company says that while attendance CPD events are permitted under UK coronavirus guidelines, it has found that many lecturers and delegates are unwilling or unable to participate in them for the time being.
The main distinction between Zoom and traditional webinars is the ability for members of the audience to see each other and the presenter, which helps engender a sense of community and of a live event. Central CPD says it gives all the feel and interactivity of attending a CPD course in person.
Central CPD is now delivering day-long events split into four sessions, which gives delegates the choice of joining for a whole day or just selected sessions.
The Zoom presentations are recorded in high definition, with the audience removed, so delegates can catch up on anything they missed later via Central CPD On-Demand.
Two days of CPD have so far been delivered via the new livestream service. Lecturer Mike Rhodes BVM&S CertVOphthal DipECVO MRCVS said: "This was my first time giving a livestream CPD day and compared to my previous experience of prerecorded lectures I found the interaction with the delegates very good fun - this could definitely be the new future with regards to veterinary CPD: COVID or no COVID!"
Livestream courses are free for subscribers or £45 + VAT per event, including unlimited access to the recorded footage afterwards.
Upcoming events for December are:
Details and booking information can be found at https://www.centralcpd.com/categories/30
Pat is the head of the Equine Studies Group at Waltham Petcare Science Institute and an internationally renowned authority on equine nutrition from both veterinary and academic perspective.
Her courses, book publications and webinars are aimed at providing practising equine vets with the latest knowledge and essential know-how on equine nutrition, whether for performance horses, leisure animals or the retired family pony.
Earlier this month Pat was one of several speakers at the British Equine Veterinary Association’s CPD course: From superfoods to supplements: How to know more than the owner.
Earlier this year she co-edited and co-authored two chapters of Veterinary Clinics Equine Practice: Nutrition: 1) What would be good for all veterinarians to know about equine nutrition, and 2) Nutritional considerations when dealing with an obese adult equine.
Next month she will chair a panel discussion titled Nutritional Management of the Competitive Equine Athlete for Vets through VetPD.
In the autumn she will be one of several speakers at the Mars Equestrian Equine Veterinary Continuing Education Series focusing on senior, obese and laminitic horses.
For more information, visit: www.spillers-feeds.com
The College says this will pave the way for new diagnostic tests for what could be one of the most common causes of pregnancy loss in mares.
The researchers, led by Dr Mandi de Mestre (pictured right), Reader in Reproductive Immunology and Head of the Equine Pregnancy Laboratory at the RVC, collaborated with seven different veterinary practices to gain access to samples from across the UK and Ireland and found that around 20% of the pregnancies lost were aneuploid, which is when a copy of a whole chromosome is either duplicated or lost (similar to Down's).
Charlotte Shilton, RVC PhD, the student who performed the analysis, applied three different genetic approaches to confirm the results.
Work is now underway to identify the underlying cause of these aneuploid pregnancies, with early data from this study suggesting it is most commonly introduced via the egg or sperm. Until now, chromosomal defects such as aneuploidy have only been reported as a rare condition in young horses with developmental disorders.
The researchers say the study explains why the condition is so rare in horses, with most embryos and foetuses possessing this genetic change dying very early in development, as is also observed in human pregnancy. The study highlights the need to reconsider this genetic condition both in pregnancy loss but also for early developmental disorders.
Dr Mandi de Mestre, Reader in Reproductive Immunology at the RVC, said: “Early pregnancy loss remains a very frustrating condition for clinicians to treat as the underlying cause is unknown in around 80% of cases. These findings will allow researchers to develop new diagnostic tests for pregnancy losses, which would offer hope to thousands of owners of breeding mares that suffer this condition.
“A diagnostic test would allow them to make informed decisions on treatment strategies and to advise on whether they should invest in further attempts to breed their mare benefiting both horses and their breeders alike in the future. I would like to thank both the Thoroughbred Breeders Association and our collaborators at Texas A&M University and the participating veterinary surgeons for their support on this project.
Zoetis, formerly Pfizer Animal Health, has launched Flexi4, a nutritional supplement for horses containing a patented combination of natural plant extracts designed to help maintain joint flexibility and the management of joint pain.
Flexi4 contains a blend of four plant extracts, Curcumin, Yucca schidigera, Salix alba and Boswellia serrata, which the company says have been shown to have anti-inflammatory, anti-pyretic and analgesic properties as follows:
Mary King, Olympic three day eventing team silver medallist, said: "When performing at the highest level it's important that my horses' joints remain flexible and free of pain. Using Flexi4 has made them more resilient to aches and pains during intense training and I am confident when competing that my horses are feeling the benefit of this natural product, helping them to perform at their very best."
Flexi4 is an apple-flavoured gel that is fed as a once daily supplement. It doesn't contain any substances listed as prohibited by the FEI.* For more information, contact your Zoetis Account Manager, call 0845 300 8034 or email customersupportuk@zoetis.com.
References
*FEI prohibited substance list, 2013
BCF has released a new bovine foetal sexing quick guide as a free download from the farm animal learning section of the company's website - www.bcftechnology.com.
To help vets learn the skill of foetal sex determination with ultrasound, the guide includes:
BCF says that using ultrasound for foetal sex determination can be useful to herd management programmes: you can estimate the number of replacement heifers, further justify the culling of a cow with chronic disease (mastitis, lameness etc.) and determine pricing for a sale and/or purchase.
The guides have been created by BCF in-house vet Kimberley Palgrave who said: "The bovine foetal sexing guide was created with the aim of giving vets a few tips to help them develop confidence in foetal sex determination using ultrasound. Hopefully this guide can help people feel more assured in their technique and enable them to obtain additional information that the farmer can use in their herd management programme."
The RCVS is advising all practices that it is not currently carrying out a data-gathering exercise and that phone calls prompting the return of a survey, and requesting mobile phone numbers, are not being made on behalf of the College.
The warning comes after several practices have called the College to query 'feedback forms' - supposedly issued in relation to the Practice Standards Scheme or the payment of members' retention fees.
The practices were asked to return forms which they had not received, and also to provide mobile phone numbers, by someone who claimed to work for the 'statutory regulator' or 'the RCVS'. Contact phone numbers left by the caller were either RCVS fax numbers or numbers which looked like RCVS direct dial numbers, but were not.
Lizzie Lockett, Head of Communications, said: "This looks like an exercise to gain mobile phone numbers which is being carried out in the College's name. We are currently investigating who might be making these calls. In the meantime, if a practice receives such a call, it would be helpful if they could take down a name and contact number and let us know."
Ring 020 7202 0725 or email l.lockett@rcvs.org.uk to report any suspicious activity.
MSD Animal Health UK has announced the launch of Bravecto, which it says is the first and only treatment available for fleas and ticks in dogs that is rapidly effective and offers 12-weeks duration of efficacy.
Bravecto (fluralaner) is the first of a new generation of systemically active ectoparasiticides, the isoxazolines, and will only be available on prescription through veterinary practices. The new product will be available in five strengths of pork liver flavoured palatable chew for different size dogs - one chew per weight band - which MSD says are readily accepted from the hand. Jolian Howell, marketing and technical lead at MSD Animal Health UK said: "Bravecto is a truly unique and exciting innovation which will transform the effective treatment of fleas and ticks - providing protection like never before from a single dose. It is the first in a new generation of products that offer a full 12-week protection and will help keep the treatment of fleas and ticks within veterinary practices."
He continued: "Estimates suggest that flea and tick treatments are applied for just 2.8 months per year so just one dose of Bravecto will immediately deliver much improved levels of treatment for dogs in veterinary care, which is good for the animal and good for the vet." MSD Animal Health says it is investing in the launch of Bravecto with a major marketing and practice support package which aims to raise awareness of fleas and ticks and drive pet owner footfall into practices for flea and tick control.
The new product will be available after BSAVA Congress, where MSD will be giving visitors the opportunity to learn more about it.
Thought to be the first agreement of its kind between a buying group and a veterinary practice, Norfolk Farm Vets and agricultural purchasing group Anglia Farmers Limited have come together to offer mutual members and clients a beneficial discount on their monthly vet account when invoiced through Anglia Farmers. Anglia Farmers livestock manager Simon Leach said: "With more than 650 livestock members, Anglia Farmers is keen to give a financial edge wherever possible. Veterinary costs are as much a part of the overall costs we already help with such as feed, equipment and fencing. In terms of dairy, they account for around 0.8p a litre of milk, accumulating to an average of around £1,200 a month for a typical East Anglian dairy of 150 head. Our discount agreement with Norfolk Farm Vets is a very positive step in aiding our members to save even more money through Anglia Farmers."Both parties agree that the time and administration cost saving benefit is equally important.Molly McKay of Norfolk Farm Vets, which has clients throughout the Eastern Counties as well as Lincolnshire, said: "Anyone involved with livestock knows how time-consuming all the paperwork can be. Each month Anglia Farmers collates all the supplier invoices, sends them on to members as part of their monthly statement with a single covering invoice which is so much easier than receiving them piecemeal. And it streamlines administration and cashflow for us as well."
Normally only accessible by ISFM members, the channel has been opened up as a free resource to help vets keep on top of CPD and includes over 40 webinars presented by internationally recognised veterinary specialists.
Topics include: anaesthesia and analgesia, behaviour, emergency and critical care, feline medicine and neurology. Each webinar is worth 1 hour of CPD and you get a certificate.
The channel includes a new webinar: ‘COVID-19 – helping cats cope’ which looks at how you can advise owners to help their cats deal with changes at home.
ISFM’s Feline Medicine Consultant, Sam Taylor said: "ISFM is committed to educating veterinary professionals on all things feline, so we are delighted to be able to bring some of our normally member-only benefits to a wider audience during this challenging time."
To register for the ISFM webinar channel, visit: https://icatcare.org/event/isfm-vet-webinars/
BlueSky says that conventional treatment for equine sarcoids, which are induced by tumour antigens E6 and E7 of the bovine papillomavirus, have only limited effect and typically result in the recurrence of the tumours.
However, research published by the company in PLoSONE1 showed that sarcoids treated with delNS/E6E7 were completely and permanently eliminated.
For the study, 29 horses were treated with different regimes involving direct injection into the tumours over three years.
Visible and very significant regression of the sarcoids was achieved in 20 of the treated horses, and 100% regression of the sarcoids in 10 equine patients.
Thomas Muster, CEO of BlueSky Immunotherapies said: "The complete elimination of very aggressive and difficult-to-cure equine sarcoids is yet another important proof of the potential offered by our delNS platform."
In addition, the systemic delNS-mediated immune stimulation eliminated non-injected sarcoids and the papillomavirus that caused the sarcoids.
Thomas added: "We are therefore confident that we will also be able to successfully heal and/or eliminate the cervical tumours of the women enrolled in the clinical trials currently under way."
The 1st Reproduction Control Guidelines of the World Small Animal Veterinary Association (WSAVA) have just been accepted for publication and are expected to recommend a move away from a blanket neutering policy.
Dr Neil Mottram BSc (Hons) BVSc MRCVS Technical Manager at Virbac said: "This webinar will help clinicians understand and navigate the latest evidence-based medicine in regards to neutering.
"The panel of world-leading experts on reproduction will present their guidance on medical and surgical neutering and offer delegates the opportunity to interact with a live Q&A section at the end of the event.
https://app.livestorm.co/virbac-france/1st-reproduction-control-guidelines?type=detailed
The sessions will be delivered by Andrew Kent, clinical director at Blaise and a small animal internal medicine specialist, Lara Dempsey, head of soft tissue surgery, Jacques Ferrerira, head of anaesthesia, Mike Farrell, head of orthopaedic surgery, and neurology clinician, Emma Suiter (pictured).
The talks will cover:
Client communication will also be covered, together with some orthopaedics for those with an interest in that area.
Andy said: “We’re building an incredible team at Blaise and are very excited at the prospect of sharing the specialist knowledge that our clinicians have with our wider veterinary community.
"Treating liver conditions can be incredibly complex and our educational programme presents an unrivalled opportunity to deep dive into this part of an animal’s body and how best to approach it.”
Tickets are available for £48 from https://www.ivcevidensiareferrals.com/Delivering-the-Best, with all profits going to the charity StreetVet.
Blaise Veterinary Referral Hospital in Longbridge is IVC’s first purpose-built pet hospital and will be open to accept referral patients from November 2023.
www.blaise-referrals.com
http://herbertsyard.com
Feliway Help! comes as a starter pack with a pheromone cartridge which lasts seven days and covers 50m2.
The cartridge is inserted into a diffuser which is plugged into an electrical socket, two days before the stressful event.
Ceva says that 83% of cat owners saw an improvement in their cat’s signs of stress after using Feliway Help!1.
The company adds that the Feliway Help! is particularly useful for clients of those practices which Feliway on the premises, with Feliway helping keep the cat calm at the practice, and Feliway Help! taking over when they return home.
Sarah Heath BVSc PgCertVE DipECAWBM(BM) CCAB FRCVS, an RCVS and EBVS European Veterinary Specialist in Behavioural Medicine and Certified Clinical Animal Behaviourist, said: “Cats can find the veterinary visit challenging and when they go home they can sometimes find it hard to settle.
"Feliway Help! can be very beneficial in easing the transition between home and the practice.
"This can be particularly helpful when cats have had a stay in hospital.”
For more information, visit www.feliway.com/uk, call the Ceva Animal Health head office on 01494 781510 or email cevauk@ceva.com.
The procedure involves introducing a catheter through the jugular, then using fluoroscopy and transoesophageal echocardiography to guide it from the right atrium through to the left side of the heart to relieve abnormal high pressures in the left atrium.
Willows says it is one of only a few centres across Europe equipped to carry out the procedure and that typically, patients who undergo TSP can be discharged from hospital the day after surgery.
Fabio Sarcinella (pictured right), an RCVS and European specialist in small animal cardiology at Willows, said: “Early clinical evaluation of the TSP procedure in humans over the last few years has shown improved quality of life and reduced clinical signs in patients with heart failure.
“The procedure has also been associated with low-risk and a meaningful drop in left atrial pressure of the affected patients.”
Fabio added: “As well as being minimally invasive, the improvement in heart chamber pressures via TSP often allows for a reduction in the dose of water tablets which are used to control the heart failure signs in the lungs.
"Lowering the dose reduces the risk of side effects related to these drugs such as kidney failure.”
Willows says TSP is most commonly used for left atrial decompression in dogs with heart failure and concurrent renal disease or that have advanced heart failure but continue to have symptoms despite optimal medical treatment.
www.willows.uk.net
Animalcare has launched a new broad spectrum fluoroquinolone antimicrobial (Enrofloxacin) which the company says is highly effective in the treatment of a wide range of conditions and easy to inject, with excellent tissue penetration.
Enrocare solution for injection is presented in three strengths: A 25mg/ml (2.5%) injection for dogs, cats and exotic animals including reptiles, small mammals and avian species. The 50mg/ml (5%) injection is licensed for use in cattle, pigs, dogs and cats, whilst the 100mg/ml (10%) injection is licensed for cattle and pigs. In the case of dogs and cats a single daily dose is needed.
Animalcare says it has priced Enrocare competitively. In addition, the range has been launched with three offers: "Buy one get one free on the 50 and 100mg/ml" and "Buy two get one free offer" on the 25mg/ml pack size. These offers will last for four months until the end of September.
In cattle, Enrocare 50mg/ml, given by the subcutaneous route, is licensed for respiratory disease of bacterial or mycoplasmal origin and the 100mg/ml strength is licenced for both respiratory disease and E.coli mastitis (the latter given by slow intravenous injection). According to Animalcare, its low dose volume makes it particularly suitable for the treatment of respiratory disease in calves. In pigs >25kg Enrocare is licensed for the treatment of the respiratory and alimentary tract diseases of bacterial or mycoplasmal origin and multi-factorial diseases such as atrophic rhinitis and enzootic pneumonia.
Tony Liepman, Animalcare Market Manager said: "The recent successful launch of Cephacare flavour raised Animalcare's profile as a supplier of more up-to-date antibiotics and this is our latest addition which offers excellent efficacy at an attractive price."
Pfizer VPS has launched a 'Pre-Sale Scab Treatment Certificate' so that sheep treated for sheep scab and protected against re-infestation beyond their autumn sale date can be formally certified as such.
A choice of two moxidectin-based treatments are eligible for use, one with 28 days and the other 60 days licensed persistency against the scab mite.
Pfizer VPS vet David Bartram explained that following treatment, the sale date must fall within the persistency window: "The idea is that farmers present their certificate at markets on sale day, then auctioneers announce the scab-protected status during their sales patter. Whether this adds to the sale price will be interesting to find out, but it's sure to be seen as a valuable attribute by buyers who won't need to treat for scab when they arrive home."
Details of the certification process are available from SQPs at animal medicine suppliers. The two eligible treatments are CYDECTIN 1% LA and CYDECTIN 2% LA for sheep.